Skip to main content

Let's Hear It for the Gloom and Doom Department

The drama continues over Pfizer's deal for Wyeth. This Review & Outlook opinion piece from the Wall Street Journal doesn't mince words about the situation, starting off with this: "Emergency is too strong a word for Pfizer's $68 billion agreement to buy Wyeth, but not by much. The deal shows the afflictions that beset the larger American pharmaceutical industry, which ought to concern anyone who cares about U.S. medical innovation." And just in case you thought there might be good news down the line, the column goes on to warn about political stumbling blocks within FDA, and refers to Pfizer's CEO as "a lawyer who came to the drug giant from McDonald's in 2006 and has been laying off scientific staff all over the place."

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.